A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 28 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Soft tissue sarcomaThis series is part of our curated briefing on it.
- Samples
- 28 samples: 8 conditions, mostly with about 4 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE276201_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1155672 and SRA study SRP528815. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 8 replicated groups read from 28 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8483658 Human_FNRMS_vehicle_1 Human_FNRMS_vehicle
- GSM8483659 Human_FNRMS_vehicle_2 Human_FNRMS_vehicle
- GSM8483660 Human_FNRMS_vehicle_3 Human_FNRMS_vehicle
- GSM8483661 Human_FNRMS_vehicle_4 Human_FNRMS_vehicle
- GSM8483662 Human_FNRMS_miR449a340_1 Human_FNRMS_miR449a340
- GSM8483663 Human_FNRMS_miR449a340_2 Human_FNRMS_miR449a340
- GSM8483664 Human_FNRMS_miR449a340_3 Human_FNRMS_miR449a340
- GSM8483665 Human_FNRMS_miR449a340_4 Human_FNRMS_miR449a340
- GSM8483666 Mouse_FNRMS_RNAseq_vehicle_1 Mouse_FNRMS_RNAseq_vehi…
- GSM8483667 Mouse_FNRMS_RNAseq_vehicle_2 Mouse_FNRMS_RNAseq_vehi…
- GSM8483668 Mouse_FNRMS_RNAseq_vehicle_3 Mouse_FNRMS_RNAseq_vehi…
- GSM8483669 Mouse_FNRMS_RNAseq_vehicle_4 Mouse_FNRMS_RNAseq_vehi…
- GSM8483670 Mouse_FNRMS_RNAseq_miR449a340_1 Mouse_FNRMS_RNAseq_miR4…
- GSM8483671 Mouse_FNRMS_RNAseq_miR449a340_2 Mouse_FNRMS_RNAseq_miR4…
- GSM8483672 Mouse_FNRMS_RNAseq_miR449a340_3 Mouse_FNRMS_RNAseq_miR4…
- GSM8483673 Mouse_FNRMS_RNAseq_miR449a340_4 Mouse_FNRMS_RNAseq_miR4…
- GSM8483674 Human_FNRMS_ATACseq_vehicle_1 Human_FNRMS_ATACseq_veh…
- GSM8483675 Human_FNRMS_ATACseq_vehicle_2 Human_FNRMS_ATACseq_veh…
- GSM8483676 Human_FNRMS_ATACseq_miR449a340_1 Human_FNRMS_ATACseq_miR…
- GSM8483677 Human_FNRMS_ATACseq_miR449a340_2 Human_FNRMS_ATACseq_miR…
- GSM8483678 Mouse_FNRMS_ATACseq_vehicle_1 Mouse_FNRMS_ATACseq_veh…
- GSM8483679 Mouse_FNRMS_ATACseq_vehicle_2 Mouse_FNRMS_ATACseq_veh…
- GSM8483680 Mouse_FNRMS_ATACseq_miR449a340_1 Mouse_FNRMS_ATACseq_miR…
- GSM8483681 Mouse_FNRMS_ATACseq_miR449a340_2 Mouse_FNRMS_ATACseq_miR…
- GSM8647165 RD18_snRNAseq_vehicle
- GSM8647166 RD18_snRNAseq_miR449a340
- GSM8647167 RD18_snATACseq_vehicle
- GSM8647168 RD18_snATACseq_miR449a340
- GSE275734 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Human_RNAseq_bulk] 8 samples same disease briefing · shares rhabdomyosarcoma, fusion-negative, multitargeting, identity, rewires
- GSE275736 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [bulk_ATACseq] 8 samples same disease briefing · shares rhabdomyosarcoma, fusion-negative, multitargeting, identity, rewires
- GSE282611 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [snRNAseq and scATACseq] 4 samples same disease briefing · shares rhabdomyosarcoma, fusion-negative, multitargeting, identity, rewires
- GSE274640 MYOD1L122R induces cancer stem cell pathways to impart chemotherapy and radiation-resistance in aggressive rhabdomyosarcoma. 80 samples same disease briefing · shares rhabdomyosarcoma
- GSE279337 Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma 40 samples same disease briefing · shares rhabdomyosarcoma
- GSE314949 RNA Seq of rhabdomyosarcoma cells with sgRNA targeting oncofusion interacting proteins 30 samples same disease briefing · shares rhabdomyosarcoma
- GSE312030 Combined inhibition of HRAS and MEK induces tumor regression and restores myogenic differentiation in HRAS-mutant rhabdomyosarcoma 159 samples same disease briefing · shares rhabdomyosarcoma
- GSE286950 PAX3-FOXO1 drives targetable cell state-dependent metabolic vulnerabilities in rhabdomyosarcoma 16 samples same disease briefing · shares rhabdomyosarcoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.